# Treatment of High Risk Adult Acute Lymphoblastic Leukemia

> **NCT00853008** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 100 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Daunorubicin
- **DRUG:** Prednisone
- **DRUG:** Mitoxantrone
- **DRUG:** Cytosine Arabinoside
- **DRUG:** Dexamethasone
- **DRUG:** Methotrexate (MTX)
- **DRUG:** Cytarabine
- **DRUG:** ASP
- **DRUG:** Mercaptopurine
- **DRUG:** Teniposide
- **DRUG:** Hydrocortisone

## Key facts

- **NCT ID:** NCT00853008
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853008, "Treatment of High Risk Adult Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00853008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*